The Global liquid biopsy market was valued at US$ 4.3 Billion in 2022, and is projected to reach US$ 7.96 Billion by 2030, growing at a CAGR of 23.4% from 2023 to 2030. Liquid biopsy is a non-invasive diagnostic tool that involves the analysis of biomarkers in body fluids such as blood, urine, or cerebrospinal fluid. It is used to detect cancer and other diseases by analyzing circulating tumor cells, cell-free DNA, and other biomolecules in the blood.

Browse 214 market data Tables and 97 Figures spread through 316 Pages and in-depth TOC on "Liquid Biopsy Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/liquid-biopsy-market-248639/

Cancer is a major health concern globally, and its incidence is increasing. Liquid biopsy offers a non-invasive diagnostic tool for the detection and monitoring of cancer. Technological advancements in liquid biopsy technologies such as next-generation sequencing, polymerase chain reaction (PCR), and microarrays have led to more accurate and sensitive detection of biomarkers in body fluids.

Market Dynamics

Liquid biopsy tests are often more expensive than traditional diagnostic tests, which may limit their adoption in certain healthcare settings or by certain patient populations. Reimbursement policies for liquid biopsy tests may be limited, which may discourage patients and healthcare providers from using these tests.

Liquid biopsy tests can be technically challenging due to the low abundance of circulating tumor cells and cell-free DNA in body fluids. This can result in false-negative or false-positive results, which may affect the accuracy of the test. There is currently a lack of standardization in liquid biopsy testing, which may make it difficult to compare results across different laboratories and diagnostic platforms.

The regulatory environment for liquid biopsy tests is complex and evolving, which may create uncertainty for manufacturers and healthcare providers.

There is significant potential for the identification of new biomarkers that can be detected through liquid biopsy. Continued research in this area may lead to the development of more accurate and sensitive tests for the early detection and monitoring of cancer. Liquid biopsy is playing an important role in the development of personalized medicine, which involves tailoring treatment to individual patients based on their specific genetic and molecular profiles. The use of liquid biopsy in this context presents significant opportunities for improving patient outcomes.

The market growth is driven by factors such as the increasing prevalence of cancer, rising demand for non-invasive diagnostic tools, and advancements in liquid biopsy technologies. The market is segmented by circulating biomarker type, clinical application, end user, and region. Circulating biomarkers include circulating tumor cells, cell-free DNA, exosomes, and other biomolecules. Clinical applications include cancer diagnosis, treatment monitoring, and early detection of cancer recurrence. End users include hospitals and laboratories, academic and research centers, and diagnostic centers.

dPCR is a highly sensitive method for the detection of nucleic acids, allowing for the detection of rare mutations in liquid biopsies. BEAMing is a digital PCR-based technology used for the detection of circulating tumor DNA (ctDNA) in liquid biopsies.

CTC enrichment and analysis technologies are used to isolate and analyze circulating tumor cells in liquid biopsies, providing information on the tumor's characteristics and response to treatment. Protein biomarker analysis is a technology used to measure specific proteins in liquid biopsies, providing information on disease status and treatment response. Exosome analysis technologies are used to isolate and analyze exosomes, which are small vesicles secreted by cells that contain nucleic acids and proteins. Exosome analysis can provide information on disease status and treatment response.

Regional Analysis

North America dominates the global liquid biopsy market due to the presence of advanced healthcare infrastructure, increasing investments in research and development, and the high incidence of cancer in the region. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period, driven by the increasing demand for personalized medicine, rising healthcare expenditure, and growing awareness about liquid biopsy technologies.

The market for liquid biopsy in Latin America is expected to grow steadily in the coming years, driven by increasing investment in healthcare infrastructure and growing awareness of liquid biopsy technology.

The market for liquid biopsy in the Middle East and Africa is also expected to grow at a steady pace, driven by increasing investment in healthcare infrastructure and growing awareness of liquid biopsy technology.

Competitive Analysis

Sysmex Corporation is a global leader in the diagnostic testing market, offering a range of liquid biopsy products for cancer detection and monitoring. Cynvenio Biosystems is a molecular diagnostics company that offers liquid biopsy products for cancer detection and monitoring.

Personal Genome Diagnostics is a biotechnology company that offers liquid biopsy products for the detection and monitoring of cancer. F. Hoffmann-La Roche AG is a global pharmaceutical company that offers liquid biopsy products for cancer detection and monitoring.

In 2021, Guardant Health acquired Bellwether Bio, a company focused on developing liquid biopsy assays for the early detection of cancer.

In 2020, QIAGEN announced a collaboration with Ares Genetics to develop and commercialize a next-generation sequencing-based test for the detection of antibiotic-resistant bacteria in blood cultures. In 2020, Roche Diagnostics announced the launch of its Elecsys® EGFR Mutation Test v2, a liquid biopsy test for the detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients

In 2020, Biocept entered into a collaboration with Aegea Biotechnologies to develop a liquid biopsy test for the detection of the SARS-CoV-2 virus. In 2019, Natera acquired Signatera, a company focused on developing personalized liquid biopsy assays for cancer detection and monitoring.

In 2019, Trovagene announced the launch of its Precision Cancer Monitoring® platform, a liquid biopsy technology for the detection and monitoring of cancer. In 2018, Sysmex Corporation acquired Silicon Valley-based company, Oxford Gene Technology, to expand its genetic analysis business, including liquid biopsy products. In 2018, Cynvenio Biosystems announced a partnership with Menarini Silicon Biosystems to develop and commercialize a liquid biopsy test for the detection and monitoring of cancer.

Segmentation Analysis of The Global Liquid Biopsy Market 2016-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global liquid biopsy market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Sample Type Outlook (Revenue, USD Million, 2017 - 2028)

• Blood Sample-based
• Others

Biomarker Outlook (Revenue, USD Million, 2017 - 2028)

• Circulating Nucleic Acids
• CTC
• Exosomes/Microvesicles
• Circulating Proteins

Technology Outlook (Revenue, USD Million, 2017 - 2028)

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America